605507.SHG Guobang Pharma Ltd
- Market cap
- CNY 12.4B
- P/E
- 19.8x
- P/B
- 1.42x
- ROE
- 7.4%
- Dividend yield
- 2.91%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 605507.SHG undervalued?
Graham number605507.SHG trades 11.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guobang Pharma Ltd fundamental analysis
No fundamental analysis for Guobang Pharma Ltd yet.
Guobang Pharma Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guobang Pharma Ltd
Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives. It sells its products approximately in 117 countries and regions worldwide. The…
Full company profileGuobang Pharma Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guobang Pharma Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 2.91B | 3.28B | 3.80B | 4.21B | 4.51B | 5.72B | 5.35B | 5.89B | 6.01B | 6.12B |
| Gross Profit | 822M | 920M | 963M | 1.41B | 1.29B | 1.53B | 1.21B | 1.44B | 1.56B | 1.42B |
| Operating Income | 469M | 580M | 582M | 936M | 809M | 1.05B | 702M | 895M | 962M | 794M |
| EBITDA | 620M | 709M | 708M | 1.16B | 1.02B | 1.21B | 950M | 1.27B | 1.45B | 732M |
| Net Income | 178M | 211M | 315M | 810M | 706M | 921M | 612M | 782M | 821M | 628M |
| EPS | 0.37 | 0.44 | 0.56 | 1.45 | 1.26 | 1.65 | 1.10 | 1.40 | 1.05 | 0.80 |
| Balance Sheet | ||||||||||
| Total Assets | 4.02B | 4.37B | 4.76B | 5.51B | 7.51B | 9.04B | 10.4B | 10.8B | 11.0B | 11.3B |
| Total Liabilities | 1.82B | 1.77B | 2.14B | 2.23B | 1.17B | 1.89B | 2.92B | 2.73B | 2.43B | 2.75B |
| Shareholders' Equity | 1.08B | 1.25B | 2.62B | 3.27B | 6.35B | 7.16B | 7.43B | 8.05B | 8.55B | 8.51B |
| Cash & Short-term Investments | 946M | 1.00B | 1.26B | 1.23B | 2.15B | 2.80B | 2.56B | 2.53B | 1.46B | 1.23B |
| Total Debt | 698M | 608M | 901M | 911M | 160M | 656M | 934M | 322M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 148M | 542M | 441M | 768M | -176M | 1.02B | 517M | 706M | 559M | - |
| Capital Expenditure | 169M | 163M | 605M | 520M | 448M | 803M | 748M | 419M | 278M | 466M |
| Free Cash Flow | -21.4M | 378M | -164M | 248M | -624M | 214M | -232M | 287M | 282M | 545M |
| Ratios | ||||||||||
| ROE | 16.5% | 16.9% | 12.0% | 24.7% | 11.1% | 12.9% | 8.2% | 9.7% | 9.6% | 7.4% |
| ROA | 4.4% | 4.8% | 6.6% | 14.7% | 9.4% | 10.2% | 5.9% | 7.3% | 7.5% | 5.6% |
| Net Profit Margin | 6.1% | 6.4% | 8.3% | 19.3% | 15.7% | 16.1% | 11.4% | 13.3% | 13.7% | 10.3% |
| Debt to Equity | 0.65x | 0.49x | 0.34x | 0.28x | 0.03x | 0.09x | 0.13x | 0.04x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guobang Pharma Ltd dividends
- Dividend yield
- 2.91%
- Forward dividend
- 0.43 CNY
- Payout ratio
- 43.8%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 360M | 0.46 | 43.8% |
| 2024 | CNY 194M | 0.35 | 24.8% |
| 2023 | CNY 362M | 0.65 | 59.0% |
| 2022 | CNY 112M | 0.20 | 12.1% |
| 2021 | CNY 279M | 0.50 | 39.6% |
| 2020 | CNY 152M | 0.27 | 18.8% |
| 2019 | CNY 34.1M | 0.06 | 10.8% |
| 2018 | 31.3M | 0.07 | 14.9% |
| 2017 | 46.4M | 0.10 | 26.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on May 29, 2026.
Who owns Guobang Pharma Ltd
- Insiders 63.51%
- Institutions 4.00%
- Public & others 32.49%
- Shares outstanding 782M
- Free float 314M
Guobang Pharma Ltd company profile
- Company name
- Guobang Pharma Ltd
- Ticker
- 605507.SHG
- ISIN
- CNE100004NS2
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 4,251
- Fiscal year end
- December
- Address
- No. 60 Xingmei Avenue, Xinchang, China, 312500
- Phone
- 86 571 8139 6120
- Website
- gbgcn.com
About Guobang Pharma Ltd
Guobang Pharma Ltd. engages in the research, development, production, and sale of products in the pharmaceutical and veterinary industries. The company offers pharmaceutical products, including quinolones, macrolides, cephalosporins, characteristic APIs, preparations and accessories, and key pharmaceutical intermediates; and mobile protection APIs, kinetophoretic preparations, and feed additives. It sells its products approximately in 117 countries and regions worldwide. The company was founded in 1996 and is based in Xinchang, China.
Guobang Pharma Ltd management
6- Mr. Shixue LiaoPresident & Director · born 1975
- Mr. Xing Cheng ShiCFO & Accounting Supervisor · born 1977
- Ms. Fangfang LuVice President · born 1977
- Mr. Qibin LiVP & Director · born 1983
- Mr. Ligao YaoVP & Director · born 1976
- Mr. Deguang PengBoard Secretary · born 1991